Dr David Graham, associate director for science in the Office of Drug Safety at FDA, alleged in a  quot;series of testy e-mail exchanges quot; that agency officials  quot;delayed and demeaned quot; the results of a study he conducted that found Vioxx -- a COX-2 inhibitor 